Navigation Links
Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood

MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Mar 7, 2007 - Gemin X announced today that a report published in the online version of the journal Blood demonstrated that its lead compound, GX15-070 (obatoclax), induced potent cytotoxic responses against patient-derived multiple myeloma tumor cells as a single-agent, and enhanced anti-myeloma effects when used as a combination therapy. GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.

"The ability of GX15-070 to inhibit tumor progression and also enhance the effects of other treatment modalities that often suffer from resistance is encouraging," stated Gordon Shore, Ph.D., Chief Scientific Officer of Gemin X. "This study describes the novel activity of this compound and supports its therapeutic use in diverse cancer types, including multiple myeloma."

In the preclinical studies, GX15-070 potently inhibited the viability of 15 of 16 human myeloma cell lines (HMCLs), including those resistant to treatment with melphalan (a chemotherapeutic) and dexamethasone (a corticosteroid). Combination studies with GX15-070 demonstrated that it enhanced the anti-myeloma activity stimulated by melphalan, dexamethasone, and bortezomib, a proteosome inhibitor. Additionally, single-agent studies of the candidate showed that it induced potent cytotoxic responses against patient-derived tumor cells without inducing cytotoxicity to human blood lymphocytes.

Gemin X is currently conducting several clinical trials of GX15-070 in multiple cancer types as a combination therapy and as a single agent. Gemin X recently initiated a Phase 1 trial with GX15-070 in combination with bortezomib in patients with mantle cell lymphoma (MCL) and a Phase 1/2 clinical trial in combination with docetaxel in patients with non-small cell lung cancer. G X15-070 is also in Phase 2 clinical trials in patients with Hodgkin's Lymphoma and in myelofibrosis with myeloid metaplasia. In multiple Phase 1 studies, GX15-070 was well-tolerated and resulted in clinical and biological activity.

The study, which is currently available in the online edition Blood, is titled, "Pre-clinical studies of the pan-Bcl inhibitor obatoclax (GX15-070) in multiple myeloma," was led by Dr. Suzanne Trudel, et al., of the Mayo Clinic of Medicine, Scottsdale, AZ, and Princess Margaret Hospital, Toronto, ON. The report will also appear in the print edition of Blood.

About Multiple Myeloma (MM)

Multiple myeloma is a type of cancer caused by malignant plasma cells that are spread throughout the bone marrow, resulting in bone erosion and interference with bone marrow and immune system function. MM is incurable and is characterized by frequent early responses to treatment followed by relapse. The American Cancer Society estimates that nearly 11,000 Americans will die of MM in 2007, and the 5-year survival rate for the disease is approximately 33 percent.

Gemin X Biotechnologies Inc. specializes in the discovery and development of novel small molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells. Gemin X's lead product, GX15-070, is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X is also developing a small molecule that induces apoptosis in p53-defective cancers. Gemin X is privately held and is located in Montreal, Quebec and Malvern, Pennsylvania. For additional information please visit Gemin X at www.geminx.com

Contact

MacDougall Biomedical Communications
Jennifer Greenleaf, 508-647-0209
or
Gemin X Biotechnologies
Sherri Carenzo, 610-640-5735 Ext. 16
scarenzo@geminx.com


'"/>




Related medicine technology :

1. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
2. Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... TOWN, Grand Cayman , May 5, 2016 ... successful trial of Oxitec , s ... reduced Aedes aegypti by 96 ... Unit (MRCU) announced a new plan to fight wild Aedes aegypti, ... of these diseases on the island of Grand Cayman . ...
(Date:5/5/2016)... Research and Markets has announced the addition of the  "Market ... to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Emission Tomography (PET) scanner and cyclotron install base in the ... France , Germany , ... United Kingdom . Along with the current ...
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Thalassaemia Market and ... their offering.       (Logo: ... Europe Thalassaemia Market and Competitive Landscape Highlights ... pipeline products, Thalassaemia epidemiology, Thalassaemia market valuations ...
Breaking Medicine Technology:
(Date:5/5/2016)... WA (PRWEB) , ... May 05, 2016 , ... ... user experience, adapted to people’s every day living patterns, Amerec, a Seattle-based steam ... computer and smart phone app. , The user interface of the app, developed ...
(Date:5/5/2016)... ... 05, 2016 , ... Talent Tech Labs (TTL) is pleased to ... National Nurses Week (May 6-12). Currently, HireNurses is a job listing and ... the Talent Tech Lab Virtual Incubation program, they will dramatically expand the functionality and ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, ... can weaken the immune system and increase inflammation, both of which raise the risk ... adult congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can ...
(Date:5/5/2016)... ... 2016 , ... T.E.N., a technology and information security executive ... the 2016 ISE® Central Executive Forum and Awards Gala at the Sheraton Downtown ... of HMS, was selected as the Information Security Executive® of the Year Award ...
(Date:5/5/2016)... ... May 05, 2016 , ... If you don’t mind a bit of prickly ... may want to consider a treatment that some have called the next great tool ... , Microneedling, also known as skin needling, is a procedure using a device covered ...
Breaking Medicine News(10 mins):